jm1c00679_si_003.csv (11.57 kB)
Download fileDiscovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme
dataset
posted on 2021-07-22, 17:11 authored by Matthew M. Hamilton, Faika Mseeh, Timothy J. McAfoos, Paul G. Leonard, Naphtali J. Reyna, Angela L. Harris, Alan Xu, Michelle Han, Michael J. Soth, Barbara Czako, Jay P. Theroff, Pijus K. Mandal, Jason P. Burke, Brett Virgin-Downey, Alessia Petrocchi, Dana Pfaffinger, Norma E. Rogers, Connor A. Parker, Simon S. Yu, Yongying Jiang, Stephan Krapp, Alfred Lammens, Graham Trevitt, Martin R. Tremblay, Keith Mikule, Keith Wilcoxen, Jason B. Cross, Philip Jones, Joseph R. Marszalek, Richard T. LewisIndoleamine
2,3-dioxygenase 1 (IDO1), a heme-containing enzyme
that mediates the rate-limiting step in the metabolism of l-tryptophan to kynurenine, has been widely explored as a potential
immunotherapeutic target in oncology. We developed a class of inhibitors
with a conformationally constrained bicyclo[3.1.0]hexane core. These
potently inhibited IDO1 in a cellular context by binding to the apoenzyme,
as elucidated by biochemical characterization and X-ray crystallography.
A SKOV3 tumor model was instrumental in differentiating compounds,
leading to the identification of IACS-9779 (62) and IACS-70465
(71). IACS-70465 has excellent cellular potency, a robust
pharmacodynamic response, and in a human whole blood assay was more
potent than linrodostat (BMS-986205). IACS-9779 with a predicted human
efficacious once daily dose below 1 mg/kg to sustain >90% inhibition
of IDO1 displayed an acceptable safety margin in rodent toxicology
and dog cardiovascular studies to support advancement into preclinical
safety evaluation for human development.